CGON · CG Oncology, Inc.
AI read · Good for CGON
The AI's read
The results could give cretostimogene a path into a group of about 50,000 patients with no approved add-on treatment. CG Oncology plans to seek FDA approval for this group in the second quarter of 2027. No severe treatment-related events or treatment-related discontinuations were reported. But the data are preliminary, and the FDA may read the full results differently. A planned application is not approval.